Disclosures for "Association Between Disease-modifying Therapies for Multiple Sclerosis and Cancer Reporting: A Disproportionality Analysis Using the U.S. Food and Drug Administration Adverse Event Reporting System Database"
-
Dr. Soysal has nothing to disclose.
-
Author has nothing to disclose
-
The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alexion. The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Roche. The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Novartis.